T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.18% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
Jones Lang LaSalle
JLL
$17.3B
| $5.54M | ﹤0.01% |
31,705
-445
| -1% | -$88.7K |
|
1402
Sensata Technologies
ST
$6.73B
| $5.53M | ﹤0.01% |
133,898
+1,394
| +1% | +$64.2K |
|
1403
LGI Homes
LGIH
$1.39B
| $5.52M | ﹤0.01% |
63,525
-169,156
| -73% | -$15.7M |
|
1404
Stoke Therapeutics
STOK
$2.02B
| $5.5M | ﹤0.01% |
416,721
-7,142
| -2% | -$109K |
|
1405
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
| $5.46M | ﹤0.01% |
65,885
+21,200
| +47% | +$1.76M |
|
1406
Regenxbio
RGNX
$711M
| $5.43M | ﹤0.01% |
219,906
-30,211
| -12% | -$755K |
|
1407
American Financial Group
AFG
$12.1B
| $5.42M | ﹤0.01% |
39,081
+152
| +0.4% | +$21.4K |
|
1408
Teva Pharmaceuticals
TEVA
$42.8B
| $5.41M | ﹤0.01% |
718,904
+68,189
| +10% | +$594K |
|
1409
Sunrun
RUN
$2.45B
| $5.34M | ﹤0.01% |
228,816
-16,189
| -7% | -$389K |
|
1410
DigitalOcean
DOCN
$15.3B
| $5.23M | ﹤0.01% |
126,489
+26,556
| +27% | +$1.18M |
|
1411
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$10.8B
| $5.13M | ﹤0.01% |
+172,667
| New | +$5.16M |
|
|
CCMP
1412
DELISTED
CMC Materials, Inc. Common Stock
CCMP
| $5.13M | ﹤0.01% |
29,402
+790
| +3% | +$140K |
|
1413
Kodiak Sciences
KOD
$2.59B
| $5.01M | ﹤0.01% |
656,418
-27,730
| -4% | -$195K |
|
1414
TIM SA
TIMB
$8.29B
| $4.98M | ﹤0.01% |
410,000
| – | – |
|
1415
Design Therapeutics
DSGN
$928M
| $4.94M | ﹤0.01% |
353,109
-220,903
| -38% | -$2.98M |
|
1416
Annaly Capital Management
NLY
$17.6B
| $4.92M | ﹤0.01% |
207,958
+11,219
| +6% | +$291K |
|
1417
Voyager Therapeutics
VYGR
$201M
| $4.89M | ﹤0.01% |
827,950
+782,850
| +1,736% | +$5.29M |
|
1418
Liberty Global Class C
LBTYK
$3.49B
| $4.88M | ﹤0.01% |
220,765
-6,800
| -3% | -$166K |
|
1419
Crown Holdings
CCK
$12.9B
| $4.83M | ﹤0.01% |
52,392
-11,533
| -18% | -$1.23M |
|
1420
Bloom Energy
BE
$67.7B
| $4.79M | ﹤0.01% |
290,365
-96,201
| -25% | -$1.76M |
|
1421
Toronto Dominion Bank
TD
$205B
| $4.72M | ﹤0.01% |
72,166
-113
| -0.2% | -$8.21K |
|
|
LBPH
1422
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $4.67M | ﹤0.01% |
1,511,739
-500
| -0% | -$2.3K |
|
1423
Lucid Motors
LCID
$2.45B
| $4.63M | ﹤0.01% |
26,967
+3,829
| +17% | +$728K |
|
|
LIAN
1424
DELISTED
LianBio American Depositary Shares
LIAN
| $4.59M | ﹤0.01% |
2,126,878
-115,511
| -5% | -$392K |
|
1425
Ryder
R
$10.1B
| $4.56M | ﹤0.01% |
64,226
-6,425
| -9% | -$471K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.